17 assets in Tinnitus

Therapeutic assets addressing Tinnitus, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Verapamil Slow Release Tinnitus	Stanford University	P4	BB (65)
Paroxetine Tinnitus	University of California, Irvine	P4	BB (64)
Topiramate Tinnitus	Stanford University	P4	BB (64)
Noramitriptyline Tinnitus	Stanford University	P4	B (63)
Amitriptyline Tinnitus	Stanford University	P4	B (62)
Apsolol Tinnitus	Stanford University	P4	B (62)
Atogepant Tinnitus	Stanford University	P4	B (62)
Candesartan Tinnitus	Stanford University	P4	B (62)
Eptinezumab Tinnitus	Stanford University	P4	B (62)
Galcanezumab Tinnitus	Stanford University	P4	B (62)
Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer Tinnitus	Stanford University	P4	B (62)
Oxygen Tinnitus	Jay C. Buckey Jr.	P4	B (62)
Acetylcysteine Tinnitus	Leading Edge Clinic	P2	CCC (53)
Betahistine Tinnitus	Leading Edge Clinic	P2	CCC (53)
Dexasone Tinnitus	Leading Edge Clinic	P2	CCC (53)
Levocarnitine Tinnitus	Leading Edge Clinic	P2	CCC (53)
Lidocaine Tinnitus	Leading Edge Clinic	P2	CCC (53)